Patents Represented by Attorney, Agent or Law Firm Susan E. Lingenfelter
-
Patent number: 8268311Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.Type: GrantFiled: September 18, 2008Date of Patent: September 18, 2012Assignee: Amgen Inc.Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
-
Patent number: 8263750Abstract: A method for purifying a protein using Protein A chromatography comprising a) absorbing the protein to Protein A immobilized on a solid support; b) removing contaminants by washing the immobilized Protein A containing the absorbed protein with a buffer comprising one or more chaotropic agents in combination with one or more hydrophobic modifiers and having a pH of at least 7.0; and c) eluting the protein from the Protein A immobilized on the solid support.Type: GrantFiled: March 16, 2007Date of Patent: September 11, 2012Assignee: Amgen Inc.Inventors: Abhinav A. Shukla, Peter Hinckley
-
Patent number: 8129167Abstract: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. Nucleic acids encoding ULBP4, vectors, and cells encoding the same are provided.Type: GrantFiled: June 5, 2009Date of Patent: March 6, 2012Assignee: Immunex CorporationInventor: David J. Cosman
-
Patent number: 7807796Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 4, 2008Date of Patent: October 5, 2010Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
-
Patent number: 7695948Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.Type: GrantFiled: February 21, 2007Date of Patent: April 13, 2010Assignee: Immunex CorporationInventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
-
Patent number: 7285643Abstract: The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: September 30, 2005Date of Patent: October 23, 2007Assignee: Immunex CorporationInventors: Timothy A. Bird, G. Duke Virca, Unja Martin, Dirk M. Anderson
-
Patent number: 7273609Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.Type: GrantFiled: August 18, 2006Date of Patent: September 25, 2007Assignee: Immunex CorporationInventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
-
Patent number: 7132264Abstract: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.Type: GrantFiled: September 2, 2005Date of Patent: November 7, 2006Assignee: Immunex CorporationInventors: Howard R. G. Clarke, Robert F. DuBose, Steven R. Wiley
-
Patent number: 7022690Abstract: Selected novel carboxylic acid substituted heterocycle compounds are effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of inflamation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: December 23, 2004Date of Patent: April 4, 2006Assignee: Amgen Inc.Inventors: Kevin Koch, Andreas Termin, John A. Josey
-
Patent number: 6627735Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.Type: GrantFiled: June 7, 2001Date of Patent: September 30, 2003Assignee: ZymoGenetics, Inc.Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
-
Patent number: 6617109Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.Type: GrantFiled: November 14, 2000Date of Patent: September 9, 2003Assignee: Corixa CorporationInventors: Jiangchun Xu, John A. Stolk
-
Patent number: 6613515Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Polypeptides and polynucleotides as provided herein may further be used for the detection and monitoring of ovarian cancer.Type: GrantFiled: August 15, 2000Date of Patent: September 2, 2003Assignee: Corixa CorporationInventors: Jiangchun Xu, John A. Stolk
-
Patent number: 6566499Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig37, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig37 polypeptides.Type: GrantFiled: February 17, 2000Date of Patent: May 20, 2003Assignee: ZymoGenetics, Inc.Inventor: Paul O. Sheppard
-
Patent number: 6537555Abstract: Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.Type: GrantFiled: June 28, 2001Date of Patent: March 25, 2003Assignee: Corixa CorporationInventors: Nancy A. Hosken, Craig H. Day, Davin C. Dillon, Patrick McGowan, Paul R. Sleath
-
Patent number: 6482612Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig39, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig39 polypeptides.Type: GrantFiled: October 10, 2000Date of Patent: November 19, 2002Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Jacqueline M. Humes
-
Patent number: 6420525Abstract: Novel ZGCL-1 transcription factor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides, agonists and antagonists may be used within methods for promoting the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.Type: GrantFiled: August 19, 1998Date of Patent: July 16, 2002Assignee: ZymoGenetics, Inc.Inventors: David P. Yee, Theresa A. Deisher
-
Patent number: 6391917Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.Type: GrantFiled: April 19, 2001Date of Patent: May 21, 2002Assignee: ZymoGenetics, Inc.Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
-
Patent number: 6372889Abstract: The present invention relates to polynucleotide and polypeptide molecules for ZTMPO-1, a novel soluble protein with homology to emerin and the thymopoietins. The polypeptides, and polynucleotides encoding them are useful for modulating cellular proliferation and differentiation and may be used for diagnostic purposes. The present invention also includes antibodies to the ZTMPO-1 polypeptides.Type: GrantFiled: April 19, 1999Date of Patent: April 16, 2002Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Darrell C. Conklin, Theresa M. Farrah, Mark F. Maurer, Angelika Grossmann
-
Patent number: 6355788Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.Type: GrantFiled: October 5, 1999Date of Patent: March 12, 2002Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Jeff L. Ellsworth
-
Patent number: 6300093Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.Type: GrantFiled: March 5, 1997Date of Patent: October 9, 2001Assignees: ZymoGenetics, Inc., University of WashingtonInventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse